Nanyang Biologics to Enter US Public Listing via $1.5B Business Combination with RF Acquisition Corp II

Nanyang Biologics Pte. Ltd., an AI drug discovery pioneer, has entered into a business combination agreement with RF Acquisition Corp II in a $1.5 billion transaction to pursue a public listing. The company offers a comprehensive drug discovery platform that integrates traditional medicine with state-of-the-art technologies and has a growing portfolio of patents across its drug-candidate pipeline and proprietary nutraceuticals.